Report : North America Label Free Detection Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Instruments and Consumables), Technology (Surface Plasmon Resonance, Bio-Layer Interferometry, Isothermal Titration Calorimetry, Differential Scanning Calorimetry, and Other LFD Technologies), Application (Binding Kinetics, Binding Thermodynamics, Endogenous Receptor Detection, Hit Confirmation, Lead Generation, and Other Applications), and End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations, and Other End Users)

The pharmaceutical and biotechnology companies segment by end user is estimated to lead the market growth during the forecast period.

According to a new market research study of “North America Label Free Detection Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Product, Technology, Application, End User and Country.” The North America label free detection market is expected to reach US$ 306.08 million by 2028 from US$ 171.84 million in 2021; it is estimated to grow at a CAGR of 8.6% from 2021 to 2028. The report highlights trends prevailing in the North America label free detection market and the factors driving market along with those that act as hindrances.

Label free technologies are relatively new in the well-established high-throughput screening (HTS) field. The technologies probe biomolecular interactions without getting affected by spatial interference, or auto-fluorescence or quenching repercussions of labels. On average, a new drug takes at least a decade to complete the journey from initial discovery to commercial launch. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), the average cost of research & development for every successful drug is ~ US$ 2.6 billion. With the rising costs of drug development to treat increasingly complex diseases, improving productivity in early drug discovery processes has been challenging.

Initially, low throughput was a significant challenge associated with label free technologies. However, the introduction of surface plasmon resonance-based (SPR-based) label free systems with higher throughput has increased the overall operational efficiency of these systems while providing valuable data to make informed decisions.

  • The latest innovation in differential scanning calorimetry (DSC) by Spectris is designed specifically for regulated environments, and the innovative technique delivers essential data to guide biopharmaceutical development. In 2017, Spectris introduced the MicroCal PEAQ-DSC microcalorimeter, which offers 24-hour operations, streamlined workflows, and automated data analysis to produce results in hours, driving productivity and efficiency gains in research and production.
  • In 2018, Danaher introduced Biacore 8K+, an eight-needle, high-sensitivity SPR system. The system automates over 4,500 experiments focused on binding between drug candidates and specific disease targets. It can be connected with the Biacore Insight Evaluation Software to translate high-quality data into actionable insights.
  •  In 2019, Agilent Technologies introduced a unique multimode real-time cell analyzer (RTCA), which blends the best of noninvasive biosensor measurements with live-cell imaging. These advancements provide label-free, real-time biosensor measurements and kinetic imaging of the same live cell populations, independently or simultaneously. This revolutionizes cell analysis in life science research.
  • In 2020, Nicoya launched Alto, a fully automated, high-throughput benchtop SPR system. It uses digital microfluidics (DMF) that replaces physical pumps, valves, or tubes with low-cost disposable cartridges. This lowers the time and cost of drug discovery, enabling scientists to understand better and fasten the process of obtaining the cure for human diseases.

Therefore, due to technological advancements, pharmaceutical and biopharmaceutical companies and academic research institutes adopt label-free technologies for biomolecular analysis during drug discovery, which fuels the growth of the label-free detection market.

The North America label free detection market based on the product is segmented into instruments and consumables. Based on technology, the label free detection market is segmented into surface plasmon resonance, bio-layer interferometry, isothermal titration calorimetry, differential scanning calorimetry, and other LFD technologies. The North America label free detection market, based on application is segmented into binding kinetics, binding thermodynamics, endogenous receptor detection, hit confirmation, lead generation, and other applications. The North America label free detection market, based on end user is segmented into pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations and other end users. Geographically, the North America label free detection market can be divided into US, Canada, and Mexico.

General Electric, Perkin Elmer, Inc., AMETEK Inc., F. HOFFMANN-LA ROCHE LTD., Spectris, METTLER TOLEDO, Agilent Technologies, Inc., Waters Corporation, Sartorius AG and Corning Incorporated are among the leading companies operating in the North America label free detection market.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id:

Download Free PDF Brochure